Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate mofetil in IgG4-related disease with IgG4 re-elevation
NCT05974683Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of mycophenolate mofetil in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Difference of relapse rate of IgG4-RD at 52 weeks. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT05974683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974683.